Bausch Health opened higher at $8.36, compared with its previous close of $8.35. In the last trading session, the stock traded between $8.24 and $8.43. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Bausch Health is now worth
$ 30.81
Resulting in a loss of
$ 69.19 (69.19%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.10 (-1.15%)
Day High
$8.43
Day Low
$8.24
Day Open
$8.36
Prev Close
$8.35
Volume
19,93,411
1W Return
-1.09%
1M Return
39.31%
3M Return
32.36%
6M Return
53.71%
1Y Return
21.20%
Fundamentals
Market Cap ($ Mn)
3,089
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
8.87%
EPS (TTM)
$1.16
Investment Returns
1 Week
-1.09%
1 Month
39.31%
3 Months
32.36%
6 Months
53.71%
9 Months
35.76%
Financials
Quarterly
All values in $ Mn
2.5K
Jun 25
2.7K
Sep 25
2.8K
Dec 25
2.5K
Mar 26
2.9K
Jun 26
2.9K
Sep 26
Updates
11Nov
Barclays raises Bausch Health price target to $9, maintains equal-weight
Barclays raised the price target for Bausch Health Companies to $9. The previous price target was set at $7. Analyst Glen Santangelo maintained an Equal-Weight rating.
Yesterday
6Nov
Bausch Health to present liver disease data at The Liver Meeting
Bausch Health presents real-world study on severe alcohol-associated hepatitis at The Liver Meeting 2026. Study of 1,630 US adults shows estimated 12-month survival rate of 62.0%. Rehospitalization rates rise from 31.4% at 30 days to 69.1% at 12 months. Liver transplantation rate recorded at 8.5% over the 12-month period.
6 days ago
30Oct
Jefferies raises Bausch Health price target to $8, maintains Hold
Jefferies raised the price target for Bausch Health Companies to $8 from $6.5. The analyst maintained a Hold rating on the stock. The revision reflects an updated valuation assessment by Young Li.
14 days ago
29Oct
Bausch Health authorizes $50 million share buyback program
Bausch Health Companies Inc. announced a new share repurchase program. The Board of Directors authorized the buyback of common shares. The total aggregate purchase price is capped at $50 million.
15 days ago
29Oct
Bausch Health Q3FY26 Results: Adjusted EBITDA up 32% to $1.3 billion
Adjusted EBITDA rose 32% YoY to $1.305 billion, exceeding $1 billion for the first time. Salix segment revenue grew 16% to $831 million, driven by Xifaxan pricing and volume. Full-year revenue guidance raised to $5.525-$5.625 billion, implying 8% YoY growth. Net debt reduced by $521 million in Q3, totaling over $1 billion YTD reduction.
15 days ago
19Oct
Bausch Health Canada expands PrOKEDI reimbursement across seven provinces
PrOKEDI coverage expanded to seven provinces including Ontario and Quebec. Federal reimbursement secured via NIHB, VAC, DND, and CSC plans. Drug offers four-week dosing interval without oral supplementation.
